title: A comparative analysis of meropenem and doripenem in febrile patients with hematologic malignancies: a single-center retrospective study.
abstract: Many patients with hematologic malignancies show immunosuppression and/or neutropenia,  and are at a high risk of developing a serious infection that would require empiric therapy  with broad-spectrum antibiotics. However, a thorough comparison of the efficacies of different  carbapenems has not been carried out. To compare the efficacies of meropenem (MEPM) and  doripenem (DRPM) in febrile patients with hematologic neoplasms, we retrospectively reviewed  data of 149 consecutive febrile patients with acute myeloid leukemia, acute lymphoblastic  leukemia, or myelodysplastic syndrome (MDS) who were treated empirically with MEPM or DRPM. The  duration from the start of carbapenem administration to decline of fever was not significantly  different between the MEPM and DRPM groups (median, 3 versus 4 days; P = 0.79). Multivariate  analysis showed that a diagnosis of MDS and the use of liposomal amphotericin-B or voriconazole  are statistically significant risk factors for sustained fever. In conclusion, MEPM and DRPM  showed similar efficacies in febrile patients with acute leukemia and MDS.
authors.affiliation: Department of Hematology & Oncology, The University of Tokyo, Tokyo 113-8655, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Toya
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Nannya
authors.forename: Kensuke
authors.initials: K
authors.lastname: Narukawa
authors.forename: Motoshi
authors.initials: M
authors.lastname: Ichikawa
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
mesh_terms: D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D015780:Carbapenems / Q000008:administration & dosage / Q000627:therapeutic use*; D000077726:Doripenem; D005260:Female; D005334:Fever / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000077731:Meropenem; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013845:Thienamycins / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D013845:Thienamycins; D000077726:Doripenem; D000077731:Meropenem